A synergistic effect of abemaciclib and the PD-L1 checkpoint blocker led to complete tumor rejection compared to tumor growth delay by the abemaciclib monotherapy and enhanced adaptive and innate immune activation (Schaer et al., 2018). The gene discussed is CD274; the disease is neoplasm.